{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:53:55Z","timestamp":1790096035223,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"am","delay-in-days":358,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030833","name":"Syneos Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030833","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","rheumatic.theclinics.com","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.rdc.2024.02.003","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T09:13:59Z","timestamp":1710234839000},"page":"281-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Immune Checkpoint Inhibitor-induced Myositis"],"prefix":"10.1016","volume":"50","author":[{"given":"Athira","family":"Jayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Suarez-Almazor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2024.02.003_bib1","article-title":"Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis","volume":"12","author":"Hamada","year":"2021","journal-title":"Front Times"},{"key":"10.1016\/j.rdc.2024.02.003_bib2","series-title":"Rheumatic diseases and syndromes induced by cancer immunotherapy","author":"Mammen","year":"2021"},{"issue":"8","key":"10.1016\/j.rdc.2024.02.003_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103375","article-title":"Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature","volume":"22","author":"Guerra","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.rdc.2024.02.003_bib4","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/art.41604","article-title":"Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors","volume":"73","author":"Aldrich","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2024.02.003_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.rdc.2024.02.003_bib6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.rdc.2024.02.003_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100791","article-title":"Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature","volume":"8","author":"Boutros","year":"2023","journal-title":"ESMO open"},{"issue":"7","key":"10.1016\/j.rdc.2024.02.003_bib8","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.rdc.2024.02.003_bib9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2018-213777","article-title":"Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1","volume":"78","author":"Mammen","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2024.02.003_bib10","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1212\/NXI.0000000000000535","article-title":"Inflammatory myopathy with myasthenia gravis: Thymoma association and polymyositis pathology","volume":"6","author":"Uchio","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.rdc.2024.02.003_bib11","article-title":"Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study","volume":"13","author":"Xie","year":"2022","journal-title":"Front Times"},{"issue":"10","key":"10.1016\/j.rdc.2024.02.003_bib12","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.rdc.2024.02.003_bib13","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdw126","article-title":"Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma","volume":"27","author":"Vallet","year":"2016","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.rdc.2024.02.003_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102455","article-title":"Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern","volume":"19","author":"Matas-Garcia","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.rdc.2024.02.003_bib15","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s40425-019-0736-4","article-title":"Tertiary lymphoid organs in the inflammatory myopathy associated with PD-1 inhibitors","volume":"7","author":"Matsubara","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"2","key":"10.1016\/j.rdc.2024.02.003_bib16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13760-020-01282-w","article-title":"Myositis as a neuromuscular complication of immune checkpoint inhibitors","volume":"120","author":"Vermeulen","year":"2020","journal-title":"Acta Neurol Belg"},{"issue":"18","key":"10.1016\/j.rdc.2024.02.003_bib17","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant Myocarditis with Combination Immune Checkpoint Blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2024.02.003_bib18","article-title":"A\u00a0Systematic Review of the Mechanisms Involved in Immune Checkpoint Inhibitors Cardiotoxicity and Challenges to Improve Clinical Safety","volume":"10","author":"Rubio-Infante","year":"2022","journal-title":"Front Times"},{"issue":"2","key":"10.1016\/j.rdc.2024.02.003_bib19","first-page":"e498","article-title":"Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors: A Systematic Literature Review","volume":"28","author":"Ghosh","year":"2022","journal-title":"J"},{"issue":"6","key":"10.1016\/j.rdc.2024.02.003_bib20","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1093\/rheumatology\/keaa832","article-title":"Anti-TIF1gamma antibody-positive dermatomyositis in a 15-year-old boy with Epstein-Barr virus-related nasopharyngeal cancer receiving nivolumab","volume":"60","author":"Asano","year":"2021","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.rdc.2024.02.003_bib21","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/ard-2022-223792","article-title":"Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis","volume":"82","author":"Pinal-Fernandez","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"10.1016\/j.rdc.2024.02.003_bib22","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in Patients Treated With Immune Checkpoint Inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.rdc.2024.02.003_bib23","article-title":"Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.rdc.2024.02.003_bib24","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00432-019-02927-x","article-title":"Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases","volume":"145","author":"Atallah-Yunes","year":"2019","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.rdc.2024.02.003_bib25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"2","key":"10.1016\/j.rdc.2024.02.003_bib26","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1136\/annrheumdis-2020-217018","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO's adverse drug reactions database","volume":"81","author":"Nguyen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2024.02.003_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.950801","article-title":"Myocarditis and myositis\/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature","volume":"9","author":"Yin","year":"2022","journal-title":"Front Med"},{"issue":"19","key":"10.1016\/j.rdc.2024.02.003_bib28","first-page":"23","article-title":"Immune Checkpoint Inhibitor-Induced Myositis\/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit","volume":"11","author":"Deharo","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.rdc.2024.02.003_bib29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ajem.2021.03.005","article-title":"Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome","volume":"46","author":"Lipe","year":"2021","journal-title":"Am J Emerg Med"},{"issue":"3","key":"10.1016\/j.rdc.2024.02.003_bib30","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/cam4.5050","article-title":"Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A single-center case series","volume":"12","author":"Longinow","year":"2023","journal-title":"Cancer Med"},{"issue":"12","key":"10.1016\/j.rdc.2024.02.003_bib31","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis\/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncol"},{"key":"10.1016\/j.rdc.2024.02.003_bib32","first-page":"21","article-title":"Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series","volume":"6","author":"Arora","year":"2020","journal-title":"Cardiooncology"},{"issue":"2","key":"10.1016\/j.rdc.2024.02.003_bib33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.rdc.2024.02.003_bib34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijcard.2019.07.025","article-title":"Diagnosis of immune checkpoint inhibitor-associated myocarditis: A systematic review","volume":"296","author":"Pradhan","year":"2019","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.rdc.2024.02.003_bib35","first-page":"05","article-title":"Cardiac Magnetic Resonance Imaging in Immune Check-Point Inhibitor Myocarditis: A Systematic Review","volume":"8","author":"Arcari","year":"2022","journal-title":"J"},{"key":"10.1016\/j.rdc.2024.02.003_bib36","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3389\/fneur.2020.00634","article-title":"Immune Checkpoint Inhibitor-Induced Myasthenia Gravis","volume":"11","author":"Huang","year":"2020","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.rdc.2024.02.003_bib37","first-page":"24","article-title":"Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series","volume":"12","author":"Marco","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"36","key":"10.1016\/j.rdc.2024.02.003_bib38","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rdc.2024.02.003_bib39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s41927-020-00144-5","article-title":"Pembrolizumab on pre-existing inclusion body myositis: a case report","volume":"4","author":"Uchio","year":"2020","journal-title":"BMC Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2024.02.003_bib40","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"4","key":"10.1016\/j.rdc.2024.02.003_bib41","first-page":"119","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"al JBAGHe","year":"2017","journal-title":"Supportive and Palliative Care"},{"issue":"4","key":"10.1016\/j.rdc.2024.02.003_bib42","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.rdc.2024.02.003_bib43","first-page":"04","article-title":"Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept","volume":"10","author":"Nguyen","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.rdc.2024.02.003_bib44","first-page":"27","article-title":"Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases","volume":"7","author":"Matzen","year":"2021","journal-title":"Cardiooncology"},{"issue":"8","key":"10.1016\/j.rdc.2024.02.003_bib45","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cjca.2018.03.012","article-title":"Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area","volume":"34","author":"Mir","year":"2018","journal-title":"Can J Cardiol"},{"issue":"20","key":"10.1016\/j.rdc.2024.02.003_bib46","article-title":"Expert Clinical Management of Severe Immune-Related Adverse Events: Results from a Multicenter Survey on Hot Topics for Management","volume":"11","author":"Riveiro-Barciela","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"5","key":"10.1016\/j.rdc.2024.02.003_bib47","first-page":"05","article-title":"Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series","volume":"11","author":"Coustal","year":"2023","journal-title":"J\u00a0Immunother Cancer"},{"issue":"7","key":"10.1016\/j.rdc.2024.02.003_bib48","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jaccas.2021.04.001","article-title":"Mogamulizumab-Associated Acute Myocarditis in a Patient With T-Cell Lymphoma","volume":"3","author":"Kwan","year":"2021","journal-title":"JACC Case Rep"},{"issue":"12","key":"10.1016\/j.rdc.2024.02.003_bib49","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1093\/rheumatology\/keab249","article-title":"Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study","volume":"60","author":"Weill","year":"2021","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.rdc.2024.02.003_bib50","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1136\/annrheumdis-2018-214336","article-title":"Immune checkpoint inhibitor rechallenge in patients with immune-related myositis","volume":"78","author":"Delyon","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X24000103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X24000103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T15:55:24Z","timestamp":1713974124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X24000103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0889857X24000103"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2024.02.003","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitor-induced Myositis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2024.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}